743P Combined analysis of overall survival (OS) from the phase III CodeBreaK 300 and phase Ib CodeBreaK 101 studies of sotorasib 960 mg plus panitumumab (soto960+pani) therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). - Kuboki, Y.; Pietrantonio, F.; Salvatore, L.; Meriggi, F.A.; Modest, D.P.; Yaeger, R.; Ruiz, E.; Taieb, J.; Karamouzis, M.V.; Esaki, T.; Kim, T.W.; Cremolini, C.; et al. (Annals of Oncology, 2025)